Clin2
NCT07314242Possibly a fitNot yet recruiting

Study of Hemay005 for moderate to severe COPD

COPD (Chronic Obstructive Pulmonary Disease)

Treatments studied

Part of Lungs & breathing clinical trials.

This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
120 people
Ages
40 years and older
Study type
Interventional

Who can take part

  • You are 40 years or older.
  • You have had COPD for at least 1 year and have a daily cough with mucus for at least 3 months in the last 2 years.
  • You use maintenance inhalers (such as steroids or long-acting bronchodilators) regularly, and your dose has not changed in the last 28 days.
  • You have not had a COPD flare-up needing steroids or antibiotics in the past 6 weeks.
  • You do not have asthma, certain other lung diseases, or active infections like hepatitis B, C, or HIV.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07658339Not yet recruiting· Phase 3
Testing an inhaled drug for COPD symptoms

This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.

Beijing
NCT07583849Recruiting· Phase 3
Testing a new inhaled powder for COPD symptoms

This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.

Beijing, Beijing Municipality
NCT07076290Not yet recruiting· Phase 1
Study of R-3750 for mild to moderate COPD

This trial tests an investigational drug called R-3750 in patients with mild to moderate COPD. It aims to see if the drug is safe and helps control symptoms. Eligible patients must have had COPD for at least a year, have mild to moderate airflow limitation, and have had at least one COPD flare-up in the past year.

NCT07634367Not yet recruiting· Phase 3
Long-term safety of HSK39004 inhaled medicine for COPD

This study tests whether a new inhaled medication called HSK39004 is safe and effective for people with moderate to severe COPD (a lung disease that makes breathing difficult). You would use this medicine regularly over a long period and have your lung function and symptoms checked.

Nanchang, Jiangxi
NCT07035652Not yet recruiting· Phase 1
Testing XH-S004 tablets for COPD over multiple doses

This trial tests an experimental tablet called XH-S004 for people with moderate-to-severe COPD. It looks at how safe the drug is, how the body processes it, and if it helps symptoms.

Beijing, Beijing Municipality
NCT06820749Enrolling by invitation· Phase 2
Study of HSK31858 tablets for lung mucus conditions

This trial tests an investigational tablet for people with chronic lung diseases like bronchiectasis, COPD, or asthma who produce at least 10 mL of sputum (mucus coughed up from the lungs) each day. The goal is to see if the drug safely reduces excess airway mucus.

Beijing, Beijing Municipality

Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.